glp-1 news september 2025 30 Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook Sen. Lesser Highlights CT's Generic
Description
Nauck MA, Mller TD
Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, glucose-dependent insulinotropic polypeptide agonists and other metabolic hormones for the treatment of chronic kidney disease
The FDA does not review compounded medications for safety, effectiveness, or quality before marketing
There are no fasting rules, no fluid restrictions, and no daily timing windows to manage
Medications including GLP-1 drugs This is a rapidly growing category
